Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Castro

Showing results (331-340 of 531) with videos related to

Pageof 54
Sort By:
The Journal of Allergy and Clinical Immunology|February 8, 2020
Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohortAnnette T Hastie, David T Mauger, Loren C Denlinger, et al.
The Journal of Clinical Investigation|February 3, 2006
Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signalsJeffrey W Tyner, Edy Y Kim, Kyotaro Ide, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|December 16, 2006
IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expressionSally E Wenzel, Silvana Balzar, Elizabeth Ampleford, et al.
Plos One|February 8, 2018
The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort studyDelphine L Chen, Howard J Huang, Derek E Byers, et al.
The Journal of Allergy and Clinical Immunology|June 1, 2011
Obesity and asthma: an association modified by age of asthma onsetFernando Holguin, Eugene R Bleecker, William W Busse, et al.
The Lancet. Respiratory Medicine|March 14, 2014
Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic studyVictor E Ortega, Gregory A Hawkins, Wendy C Moore, et al.
American Journal of Respiratory and Critical Care Medicine|February 5, 2021
Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research ProgramAnnette T Hastie, David T Mauger, Loren C Denlinger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid DoseChristian Domingo, Jorge F Maspero, Mario Castro, et al.
Pageof 54

Showing results (331-340 of 531) with videos related to

Sort By:
Pageof 54
The Journal of Allergy and Clinical Immunology|February 8, 2020
Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohortAnnette T Hastie, David T Mauger, Loren C Denlinger, et al.
The Journal of Clinical Investigation|February 3, 2006
Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signalsJeffrey W Tyner, Edy Y Kim, Kyotaro Ide, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|December 16, 2006
IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expressionSally E Wenzel, Silvana Balzar, Elizabeth Ampleford, et al.
Plos One|February 8, 2018
The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort studyDelphine L Chen, Howard J Huang, Derek E Byers, et al.
The Journal of Allergy and Clinical Immunology|June 1, 2011
Obesity and asthma: an association modified by age of asthma onsetFernando Holguin, Eugene R Bleecker, William W Busse, et al.
The Lancet. Respiratory Medicine|March 14, 2014
Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic studyVictor E Ortega, Gregory A Hawkins, Wendy C Moore, et al.
American Journal of Respiratory and Critical Care Medicine|February 5, 2021
Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research ProgramAnnette T Hastie, David T Mauger, Loren C Denlinger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid DoseChristian Domingo, Jorge F Maspero, Mario Castro, et al.
Pageof 54